Why single-payer health systems may struggle with cutting-edge biomedical innovation
The article argues that single-payer government-run health care systems are adequate for routine, established medical treatments but perform poorly when it comes to developing, financing, and delivering cutting-edge, personalized, and expensive biomedical innovations. The author contends that as medicine advances toward personalized genomic immunotherapies costing hundreds of thousands of dollars, innovation capacity will become the most critical factor, and government-run systems are ill-equipped to handle this future.
Key quotes
Government-run systems often (not always) do a perfectly fine job setting a broken arm or administering a long-standing, well-known medication.
They do much less well when it comes to developing, financing, and delivering a new immunological approach to fighting cancer, personalized to your individual genome at a cost of hundreds of thousands of dollars.
In our rapidly arriving biomedical future, innovation capacity will matter above all else.
From the article
You might also wanna read
UK Life Sciences Must Move From Innovation Pilots to National Adoption
Distributed Biomanufacturing: Rethinking Production and Logistics for Autologous Cell Therapies
'Can't treat our way out': Why Australia's $271 billion health spend could miss the mark
Personalized health tech promises fall short for chronic condition patients
This article is a personal narrative from a Verge senior reviewer discussing the gap between the promises of personalized health technology
The Verge·1mo ago
U.S. restrictions on Chinese biotech could harm patients, argues editorial
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec
The Economist·18d agoU.S. restrictions on Chinese biotech could harm patients, argues editorial
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec
economist.com·18d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.